U.S. Physical Therapy, Inc. (USPH)
NYSE: USPH · Real-Time Price · USD
73.56
-0.63 (-0.85%)
Jul 17, 2026, 4:00 PM EDT - Market closed

U.S. Physical Therapy Earnings Call Transcripts

Fiscal Year 2026

  • Q1 2026 revenue rose 7.9% year-over-year, driven by higher patient volumes and strong commercial rates, despite weather-related disruptions. Guidance for full-year adjusted EBITDA of $102–$106 million was reaffirmed, with hospital partnerships and acquisitions expected to ramp up contributions in the second half.

Fiscal Year 2025

  • Adjusted EBITDA and net revenue grew over 16% year-over-year, with record patient visit volumes and strong margin improvement despite Medicare headwinds. Two exclusive hospital alliances and multiple acquisitions are set to drive further growth and margin expansion in 2026.

  • Record Q2 with strong revenue and margin growth in both physical therapy and injury prevention segments, driven by acquisitions, operational efficiencies, and robust demand. Raised full-year adjusted EBITDA guidance and authorized a $25M share repurchase program.

  • A partnership-driven physical therapy network continues double-digit growth despite Medicare headwinds, leveraging disciplined acquisitions, operational efficiency, and a rapidly expanding industrial injury prevention segment with high margins and strong organic growth.

  • Record Q2 driven by strong growth in physical therapy and industrial injury prevention, with adjusted EBITDA up 21% year-over-year. Raised 2025 guidance, expanded margins, and launched a $25M share repurchase program, while continuing to invest in technology and acquisitions.

  • Operating nearly 800 clinics in 44 states, the company leverages a partnership and acquisition model to drive growth in a fragmented $40B rehab market. Revenue is diversified across commercial, Medicare, and workers’ comp, with Medicare rates set to rise in 2026. Industrial injury prevention is a fast-growing, high-margin segment.

  • Record Q1 visits per clinic and 16.4% revenue growth were achieved despite weather and Medicare headwinds, with strong March performance and robust IIP segment growth. Metro acquisition contributed significantly, and margin improvement is expected as rate negotiations and operational initiatives progress.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021